Search
Monopar Therapeutics Inc
MNPRAdd to Watchlist
72.000USD
-0.680-0.94%
Close 11-13 16:00（ET）
483.12MMarket Cap
LossP/E TTM
After-hours 19:06 (ET)72.000USD+0.375+0.52%
After-hours 19:06 (ET)Monopar Therapeutics Inc (MNPR) Stock Price Target & Forecast
Analyst Rating
Based on 13 analysts giving stock ratings to Monopar Therapeutics Inc in the past month.
Buy
2 Strong Buy
10 Buy
1 Hold
0 Sell
0 Strong Sell
Target Price
127.417USD+81.20%
MNPR Analyst Recommendation Trends
In the current month, MNPR has received 10 Buy Ratings, 1 Hold Ratings, and 0 Sell Ratings. MNPR average Analyst price target in the last month is 127.417.
2026-11
2026-10
2026-09
2026-08
2026-07
2026-06
2026-05
2026-04
2
2
2
2
2
3
3
3
10
10
11
11
11
11
11
11
1
1
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
13
13
13
13
13
14
14
14
MNPR Analyst Rating for Peer Comparison
Updated: Nov 5, 2026Company name
Strong Buy
Buy
Hold
Sell
Strong Sell
Analysts
argenx SE
ARGX
10
14
3
0
0
27
Beigene Ltd
ONC
8
19
0
0
0
27
Ionis Pharmaceuticals Inc
IONS
6
16
4
0
0
26
Insmed Inc
INSM
6
18
1
0
0
25
Revolution Medicines Inc
RVMD
10
14
1
0
0
25
Ascendis Pharma A/S
ASND
9
13
1
0
0
23
CRISPR Therapeutics AG
CRSP
4
8
11
0
0
23
Kymera Therapeutics Inc
KYMR
9
12
2
0
0
23
Tempus AI Inc
TEM
4
7
11
0
1
23
Biontech SE
BNTX
4
12
6
0
0
22
Financial Forecasting
Based on analysts' estimates, MNPR EPS is projected to reach -1.162 in FY2026Q4, following reported EPS of -0.724 in FY2026Q3. Track earnings expectations against reported figures to see how profitability is evolving.
EPS
Revenue
Net Profit
EBIT
Forecast
Actual
FY2026Q1
FY2026Q2
FY2026Q3
FY2026Q4
FY2027Q1
Forecast
-0.84
-0.62
-0.87
-1.16
-1.16
Actual
0.46
-0.62
-0.72
--
--
Surprise
+155.06%
-0.15%
+16.75%
--
--
FAQs
What is Monopar Therapeutics Inc's price target?
Analysts forecast that Monopar Therapeutics Inc's price target is USD 127.42, with the highest forecast at USD 145.00 and the lowest forecast at USD 100.00.
How have Monopar Therapeutics IncMNPR's recent earnings per share performed?
The market expectation was USD -0.72, while Monopar Therapeutics IncMNPR's earnings per share (EPS) for the previous quarter was USD -0.62. EPS for the next quarter is expected at USD -1.16.
What is the analyst rating for Monopar Therapeutics Inc?
Based on the ratings of Monopar Therapeutics Inc's stock from 13 analysts, most analysts support a Buy trend. After considering the opinions of other analysts, we ultimately rate Apple's stock as Buy. Please note that this is not trading advice. You still need to conduct your own analysis.